

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

February 9, 2026

**Consolidated Financial Results  
for the Nine Months of the Fiscal Year Ending March 31, 2026  
(Under Japanese GAAP)**

Company name: OSAKA SODA Co., Ltd.  
 Listing: Tokyo Stock Exchange  
 Securities code: 4046  
 URL: <http://www.osaka-soda.co.jp>  
 Representative: Kenshi Terada, Representative Director, President and Chief Executive Officer  
 Inquiries: Toru Imamura, Executive Officer, General Manager, Administration Division  
 Telephone: +81-6-7733-1001  
 Scheduled date to commence dividend payments : —  
 Preparation of supplementary material on financial results : None  
 Holding of financial results briefing : None

(Yen amounts are rounded down to millions, unless otherwise noted.)

**1. Consolidated financial results for the Nine months ended December 31, 2025 (from April 1, 2025 to December 31, 2025)**

**(1) Consolidated operating results (cumulative)** (Percentages indicate year-on-year changes.)

|                   | Net sales       |       | Operating profit |      | Ordinary profit |      | Profit attributable to owners of parent |      |
|-------------------|-----------------|-------|------------------|------|-----------------|------|---|------|
| Nine months ended | Millions of yen | %     | Millions of yen  | %    | Millions of yen | %    | Millions of yen                         | %    |
| December 31, 2025 | 73,688          | (1.3) | 12,937           | 21.6 | 14,619          | 24.9 | 10,640                                  | 34.0 |
| December 31, 2024 | 74,650          | 6.3   | 10,639           | 40.0 | 11,700          | 36.1 | 7,940                                   | 49.9 |

Note: Comprehensive income For the Nine months ended December 31, 2025: ¥14,725 million [90.9%]  
 For the Nine months ended December 31, 2024: ¥7,714 million [(1.5)%]

|                   | Basic earnings per share | Diluted earnings per share |
|-------------------|--------------------------|----------------------------|
| Nine months ended | Yen                      | Yen                        |
| December 31, 2025 | 84.92                    | —                          |
| December 31, 2024 | 62.59                    | —                          |

Note: The Company implemented a 5-for-1 stock split for common shares with an effective October 1, 2024.  
 Basic earnings per share is calculated based on the assumption that the stock split was implemented at the beginning of previous fiscal year.

**(2) Consolidated financial position**

|                   | Total assets               | Net assets                 | Equity-to-asset ratio |
|-------------------|----------------------------|----------------------------|-----------------------|
| As of             |                            |                            | %                     |
| December 31, 2025 | Millions of yen<br>162,974 | Millions of yen<br>122,952 | 75.4                  |
| March 31, 2025    | 153,935                    | 115,596                    | 75.1                  |

Reference: Equity  
 As of December 31, 2025: ¥122,948 million  
 As of March 31, 2025: ¥115,591 million

## 2. Cash dividends

|   | Annual dividends per share |                    |                   |                 |       | Yen |
|---|----------------------------|--------------------|-------------------|-----------------|-------|-----|
|   | First quarter-end          | Second quarter-end | Third quarter-end | Fiscal year-end | Total |     |
| Fiscal year ended March 31, 2025                | —                          | Yen<br>45.00       | —                 | Yen<br>10.00    | —     | Yen |
| Fiscal year ending March 31, 2026               | —                          | 12.00              | —                 | —               | —     | —   |
| Fiscal year ending March 31, 2026<br>(Forecast) | —                          | —                  | —                 | 13.00           | 25.00 | —   |

Note: 1. Revisions to the forecast of cash dividends most recently announced: None

2. The Company implemented a 5-for-1 stock split for common shares with an effective October 1, 2024. For the fiscal year ended March 31, 2025, the interim dividend is presented based on the number of shares before the stock split, while the year-end dividend is shown based on the number of shares after the stock split. As a result, the total full-year dividend is displayed as “—”.

## 3. Consolidated financial results forecasts for the fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

|           | Net sales       |     | Operating profit |      | Ordinary profit |      | Profit attributable to owners of parent |      | Basic earnings Per share |
|-----------|-----------------|-----|------------------|------|-----------------|------|---|------|--------------------------|
|           | Millions of yen | %   | Millions of yen  | %    | Millions of yen | %    | Millions of yen                         | %    | Yen                      |
| Full year | 102,000         | 5.8 | 17,300           | 30.6 | 18,700          | 32.1 | 13,500                                  | 30.7 | 108.28                   |

Note: 1. Revisions to the forecast of consolidated financial results most recently announced: None

\* **Notes**

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

- (i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
- (ii) Changes in accounting policies due to other reasons: None
- (iii) Changes in accounting estimates: None
- (iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

|                         |                    |
|-------------------------|--------------------|
| As of December 31, 2025 | 133,660,085 shares |
| As of March 31, 2025    | 133,660,085 shares |

(ii) Number of treasury shares at the end of the period

|                         |                   |
|-------------------------|-------------------|
| As of December 31, 2025 | 10,186,175 shares |
| As of March 31, 2025    | 7,804,540 shares  |

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

|                                     |                    |
|-------------------------------------|--------------------|
| Nine months ended December 31, 2025 | 125,289,529 shares |
| Nine months ended December 31, 2024 | 126,866,152 shares |

Note: Total number of issued shares at the end of the period, Number of treasury shares at the end of period and Average number of shares outstanding during the period are calculated based on the assumption that the stock split was implemented at the beginning of previous fiscal year.

\* Review of the Japanese-language originals of the attached consolidated quarterly consolidated financial statement contained in this report by certified public accountants or an audit corporation: None

\* Proper use of earnings forecasts, and other special matters

In this document, statements other than historical facts are forward looking statements that reflect the Company's plans and expectations. These forward-looking statements involve risks, uncertainties and other factors that may cause our actual results and achievements to differ from those anticipated in these statements. Please refer to "1. Overview of operating results, etc. (3) Analysis of Forward-looking Statement, Including Consolidated financial results Forecasts" on page 4 of the attached documents.

(Attached Documents)

INDEX

|   |    |
|---|----|
| 1. Overview of operating results, etc.  | 2  |
| (1) Overview of operating results for the first nine months                                   | 2  |
| (2) Overview of financial position for the first nine months                                  | 3  |
| (3) Analysis of forward-looking statement, including consolidated financial results forecasts | 4  |
| 2. Quarterly Consolidated Financial Statements and significant notes thereto                  | 5  |
| (1) Consolidated Balance Sheets   | 5  |
| (2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income     | 7  |
| (3) Notes to Quarterly Consolidated Financial Statements                                      | 9  |
| (Notes on Premise of Going Concern)   | 9  |
| (Notes on Major Changes in Shareholders' Equity)  | 9  |
| (Notes on Quarterly Consolidated Statements of Cash Flows)                                    | 9  |
| (Notes on Segment Information and Other Items)  | 10 |

## 1. Overview of operating results, etc.

### (1) Overview of operating results for the first nine months

During the first nine months of the current consolidated fiscal year, the Japanese economy continued its gradual recovery, with an improvement in the employment and income situation and a pickup in consumer spending and capital investment. On the other hand, the risk of a downward swing in the economy is increasing due to factors such as the impact of U.S. tariffs, stagnation of the Chinese economy, and continuing price hikes, and the outlook remains uncertain.

In light of these circumstances, for this final year of our medium-term management plan, Shape the Future-2025 (FY2023 to FY2025), our group has been steadily implementing specific measures in line with the plan's three basic policies: continuous strengthening of our base in existing businesses, strengthening of new product creation capabilities, and promotion of sustainability management.

In terms of the "continuous strengthening of our base in existing businesses," we have been working to enhance our business base by generating stable cash flows and actively investing in growth areas. In the Basic chemicals business, in addition to efforts aimed at reducing costs, we have been working to improve profitability by aggressively expanding sales of Epichlorohydrin as overseas market conditions improve. We will continue to invest in upgrading facilities to improve production efficiency and reduce costs in order to strengthen business foundations so that we can generate stable earnings. In the Functional chemicals business, we were able to increase sales by promoting sales expansion activities to existing customers and promoting new business development, but sales for some products decreased as a result of reduced demand. For Allyl Ethers, we have increased the capacity of our shipping facilities this fiscal year and plan to increase production capacity by approximately 1.2 times the current level by March 2027, further solidifying our position as having one of the world's top market shares. In the Healthcare business, the demand for pharmaceutical purification materials for diabetes and obesity medications has continued to expand, and sales volume has been steadily increasing.

Following the completion of new facilities at the Matsuyama Plant in September 2024 and the expansion of the Amagasaki Plant in September 2025, approximately one year ahead of schedule, production capacity has approximately doubled compared to FY2023, and a supply system is now in place that can meet the current increase in demand. Furthermore, in light of the rapid development of generic entry and biosimilars, we have decided to approximately double the current capacity at the Amagasaki and Matsuyama Plants by February 2028, at a total cost of over 10 billion yen. Through a series of capital investments, we will secure an even more stable supply system and strengthen our competitiveness.

In terms of the "strengthening of new product creation capabilities," the development of materials for next-generation storage batteries, such as ultra-high ionic conductive polymers for all-solid batteries, which were selected as a NEDO Green Innovation Fund project, is progressing smoothly. We are considering building a pilot facility during this fiscal year to establish a mass production system.

Regarding the size exclusion and highly alkali-resistant columns launched last year, we are working to expand new adoption and sales are steadily increasing. For ADME gel for preparative use, we have started sample work for customers in working toward adoption.

For lactic acid bacterium OS-1010, following its function of maintaining skin elasticity, we started human trials on maintaining cognitive function, etc., which has been progressing smoothly.

In terms of the "promotion of sustainability management," we have reviewed our policy on ESG disclosure initiatives and improved our ESG score. We are expanding opportunities for dialogue with institutional investors, and, taking into account the opinions obtained through such discussions, we are working to enhance shareholder returns by improving capital efficiency and introducing progressive dividends.

Aiming to develop human resources by promoting operational reform activities as an investment in human capital, we are working to create a comfortable work environment and improve employee engagement. As part of this effort, we relocated our head office in August 2025 to revitalize communication and attract a diverse and talented workforce.

Net sales for first nine months of the current consolidated fiscal year decreased 1.3% year on year to ¥73,688 million. In terms of profit, operating profit increased 21.6% year on year to ¥12,937 million, ordinary profit increased 24.9% year on year to ¥14,619 million, and profit attributable to owners of parent increased 34.0% year on year to ¥10,640 million.

#### < Basic chemicals >

Net sales of Chlor-Alkali products increased due to an increase in sales volume resulting from the resolution of supply problems caused by the manufacturing equipment problems at the Mizushima Plant.

Net sales of Epichlorohydrin increased due to an increase in sales volume resulting from the resolution of supply problems and improved overseas market conditions.

As a result of the above, net sales in the Basic chemicals business increased 9.7% year on year to ¥30,842 million.

#### < Functional chemicals >

In the Synthetic rubbers business, net sales of Acrylic Rubber increased due to increased production capacity resulting from the completion of last year's debottlenecking, but net sales of Epichlorohydrin Rubber decreased due to a decline in automobile production in regions such as Europe.

For synthetic resins, net sales of DAP resin increased due to strong sales in Europe, and net sales of DAP monomer increased due to replacing competing products in the U.S.

Net sales of Allyl Ethers decreased due to the fact that, although there were signs of improvement, the Chinese market has not yet recovered to the previous year's level.

As a result of the above, net sales in the Functional chemicals business decreased 10.9% year on year to ¥20,604 million.

#### <Healthcare>

Net sales of pharmaceutical purification materials increased due to a steady growth in demand for diabetes and obesity medications. Net sales of active pharmaceutical ingredients (APIs) and their intermediates decreased, as although sales of nucleic acid drug and intermediates for anticancer drugs increased, sales of intermediates of medications for diabetes complications and osteoporosis drug substances decreased.

As a result of the above, net sales in the Healthcare business increased 5.1% year on year to ¥10,376 million.

#### <Trading and Others>

Net sales decreased due to a decline in sales of inorganic chemicals and building materials.

As a result of the above, net sales in the Trading and others business decreased 12.4% year on year to ¥11,865 million.

### (2) Overview of financial position for the first nine months

#### (Assets)

Current assets were ¥95,134 million, an increase of 2.4% since March 31, 2025. This was due primarily to an increase of ¥2,666 million in notes and accounts receivable - trade, and contract assets. Noncurrent assets were ¥67,839 million, an increase of 11.2% since March 31, 2025. This was due primarily to increases of ¥781 million in non-current assets and ¥5,853 million in investment securities. As a result, total assets at the end of the first nine months of the consolidated accounting period were ¥162,974 million, an increase of 5.9% since March 31, 2025.

#### (Liabilities)

Current liabilities were ¥31,197 million, a decrease of 0.6% since March 31, 2025. This was due primarily to an increase of ¥2,651 million notes and accounts payable - trade and decreases of ¥823 million in income taxes payable and ¥1,463 million in accounts payable-other included in other. Noncurrent liabilities were ¥8,823 million, an increase of 26.9% since March 31, 2025. This was due primarily to an increase of ¥1,781 million in deferred tax liabilities. As a result, liabilities at the end of the first nine months of the consolidated accounting period were ¥40,021 million, an increase of 4.4% since March 31, 2025.

#### (Net assets)

Net assets at the end of the first nine months of the consolidated accounting period were ¥122,952 million, an increase of 6.4% since March 31, 2025. This was due primarily to an increase of ¥7,877 million in retained earnings.

(3) Analysis of forward-looking statement, including consolidated financial results forecasts

There have been no changes to the full-year performance forecast for the fiscal year ending March 2026 announced on November 7, 2025. We will disclose any changes in the future as appropriate.

2. Quarterly Consolidated Financial Statements and significant notes thereto

(1) Consolidated Balance Sheets

(Millions of yen)

|  | As of March 31, 2025  | As of December 31, 2025 |
|--|-----------------------|-------------------------|
| <b>Assets</b>  |                       |                         |
| Current assets   |                       |                         |
| Cash and deposits  | 16,339                | 16,148                  |
| Notes and accounts receivable - trade, and contract assets | 25,742                | 28,408                  |
| Electronically recorded monetary claims - operating        | 4,576                 | 6,290                   |
| Securities   | 26,974                | 24,965                  |
| Merchandise and finished goods                             | 9,817                 | 9,546                   |
| Work in process  | 2,280                 | 3,388                   |
| Raw materials and supplies                                 | 5,707                 | 4,613                   |
| Other  | 1,496                 | 1,795                   |
| Allowance for doubtful accounts                            | △19                   | △22                     |
| Total current assets                                       | <u>92,916</u>         | <u>95,134</u>           |
| Non-current assets   |                       |                         |
| Property, plant and equipment                              |                       |                         |
| Buildings and structures, net                              | 9,490                 | 9,497                   |
| Machinery, equipment and vehicles, net                     | 14,675                | 14,490                  |
| Land   | 2,246                 | 2,246                   |
| Leased assets, net   | 531                   | 476                     |
| Construction in progress                                   | 1,979                 | 2,961                   |
| Other, net   | 371                   | 403                     |
| Total property, plant and equipment                        | <u>29,295</u>         | <u>30,076</u>           |
| Intangible assets  |                       |                         |
| Goodwill   | 118                   | 84                      |
| Software   | 82                    | 51                      |
| Other  | 1,320                 | 2,123                   |
| Total intangible assets                                    | <u>1,521</u>          | <u>2,259</u>            |
| Investments and other assets                               |                       |                         |
| Investment securities                                      | 28,510                | 34,363                  |
| Long-term loans receivable                                 | 9                     | 7                       |
| Deferred tax assets  | 715                   | 222                     |
| Other  | 1,544                 | 1,488                   |
| Allowance for doubtful accounts                            | △578                  | △577                    |
| Total investments and other assets                         | <u>30,201</u>         | <u>35,503</u>           |
| Total non-current assets                                   | <u>61,018</u>         | <u>67,839</u>           |
| <b>Total assets</b>  | <b><u>153,935</u></b> | <b><u>162,974</u></b>   |

(Millions of yen)

|   | As of March 31, 2025 | As of December 31, 2025 |
|---|----------------------|-------------------------|
| <b>Liabilities</b>                                    |                      |                         |
| <b>Current liabilities</b>                            |                      |                         |
| Notes and accounts payable - trade                    | 13,117               | 15,769                  |
| Short-term borrowings                                 | 7,172                | 7,172                   |
| Current portion of long-term borrowings               | 76                   | —                       |
| Income taxes payable                                  | 2,947                | 2,123                   |
| Provision for bonuses                                 | 953                  | 477                     |
| Other   | 7,119                | 5,655                   |
| <b>Total current liabilities</b>                      | <b>31,385</b>        | <b>31,197</b>           |
| <b>Non-current liabilities</b>                        |                      |                         |
| Long-term borrowings                                  | 387                  | —                       |
| Lease liabilities                                     | 675                  | 588                     |
| Deferred tax liabilities                              | 3,973                | 5,755                   |
| Retirement benefit liability                          | 1,207                | 1,040                   |
| Asset retirement obligations                          | 557                  | 657                     |
| Other   | 150                  | 782                     |
| <b>Total non-current liabilities</b>                  | <b>6,953</b>         | <b>8,823</b>            |
| <b>Total liabilities</b>                              | <b>38,339</b>        | <b>40,021</b>           |
| <b>Net assets</b>                                     |                      |                         |
| <b>Shareholders' equity</b>                           |                      |                         |
| Share capital   | 15,871               | 15,871                  |
| Capital surplus                                       | 17,020               | 17,026                  |
| Retained earnings                                     | 76,151               | 84,028                  |
| Treasury shares                                       | △6,410               | △11,021                 |
| <b>Total shareholders' equity</b>                     | <b>102,633</b>       | <b>105,905</b>          |
| <b>Accumulated other comprehensive income</b>         |                      |                         |
| Valuation difference on available-for-sale securities | 11,316               | 15,352                  |
| Deferred gains or losses on hedges                    | △56                  | 88                      |
| Foreign currency translation adjustment               | 1,026                | 957                     |
| Remeasurements of defined benefit plans               | 671                  | 644                     |
| <b>Total accumulated other comprehensive income</b>   | <b>12,957</b>        | <b>17,042</b>           |
| <b>Non-controlling interests</b>                      | <b>4</b>             | <b>4</b>                |
| <b>Total net assets</b>                               | <b>115,596</b>       | <b>122,952</b>          |
| <b>Total liabilities and net assets</b>               | <b>153,935</b>       | <b>162,974</b>          |

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

Consolidated Statements of Income

(Millions of yen)

|  | Nine months ended<br>December 31, 2024 | Nine months ended<br>December 31, 2025 |
|--|--|--|
| Net sales  | 74,650                                 | 73,688                                 |
| Cost of sales  | 52,664                                 | 49,080                                 |
| Gross profit   | 21,985                                 | 24,608                                 |
| Selling, general and administrative expenses                     | 11,346                                 | 11,670                                 |
| Operating profit   | 10,639                                 | 12,937                                 |
| Non-operating income   |  |  |
| Interest income  | 47                                     | 124                                    |
| Dividend income  | 762                                    | 1,066                                  |
| Share of profit of entities accounted for using<br>equity method | 14                                     | 19                                     |
| Foreign exchange gains   | 202                                    | 365                                    |
| Subsidy income   | 134                                    | 144                                    |
| Other  | 110                                    | 95                                     |
| Total non-operating income                                       | 1,272                                  | 1,816                                  |
| Non-operating expenses   |  |  |
| Interest expenses  | 90                                     | 105                                    |
| Loss on tax purpose reduction entry of<br>non-current assets     | 35                                     | —                                      |
| Other  | 85                                     | 28                                     |
| Total non-operating expenses                                     | 210                                    | 134                                    |
| Ordinary profit  | 11,700                                 | 14,619                                 |
| Extraordinary income   |  |  |
| Gain on sale of businesses                                       | —                                      | 312                                    |
| Gain on sale of investment securities                            | —                                      | 609                                    |
| Total extraordinary income                                       | —                                      | 921                                    |
| Extraordinary losses   |  |  |
| Loss on retirement of non-current assets                         | 115                                    | 251                                    |
| Head office relocation expenses                                  | —                                      | 62                                     |
| Loss on valuation of investment securities                       | 15                                     | —                                      |
| Total extraordinary losses                                       | 131                                    | 314                                    |
| Profit before income taxes                                       | 11,568                                 | 15,226                                 |
| Income taxes - current   | 3,403                                  | 4,249                                  |
| Income taxes - deferred  | 227                                    | 335                                    |
| Total income taxes   | 3,631                                  | 4,585                                  |
| Profit   | 7,936                                  | 10,641                                 |
| Profit (Loss) attributable to non-controlling<br>interests       | △3                                     | 1                                      |
| Profit attributable to owners of parent                          | 7,940                                  | 10,640                                 |

Consolidated Statements of Comprehensive Income

(Millions of yen)

|   | Nine months ended<br>December 31, 2024 | Nine months ended<br>December 31, 2025 |
|---|--|--|
| Profit  | 7,936                                  | 10,641                                 |
| Other comprehensive income  |  |  |
| Valuation difference on available-for-sale securities                             | △279                                   | 4,036                                  |
| Deferred gains or losses on hedges  | 34                                     | 144                                    |
| Foreign currency translation adjustment   | 24                                     | △50                                    |
| Remeasurements of defined benefit plans, net of tax                               | △11                                    | △26                                    |
| Share of other comprehensive income of entities accounted for using equity method | 8                                      | △20                                    |
| Total other comprehensive income  | △222                                   | 4,083                                  |
| Comprehensive income  | 7,714                                  | 14,725                                 |
| Comprehensive income attributable to  |  |  |
| Comprehensive income attributable to owners of parent                             | 7,718                                  | 14,725                                 |
| Comprehensive income attributable to non-controlling interests                    | △3                                     | 0                                      |

(3) Notes to Quarterly Consolidated Financial Statements

(Notes on Premise of Going Concern)

Not applicable

(Notes on Major Changes in Shareholders' Equity)

The Company acquired 524,300 shares pursuant to the resolution approved at the Board of Directors meeting held on August 8, 2025, and 1,862,800 shares pursuant to the resolution approved at the Board of Directors meeting held on November 7, 2025. As a result, treasury shares increased by 4,615 million yen during the nine-month period of the fiscal year ending March 31, 2026.

(Notes on Quarterly Consolidated Statements of Cash Flows)

Quarterly consolidated statements of cash flows for the Nine months of the current consolidated fiscal year have not been prepared. Depreciation expenses (including amortization related to intangible fixed assets excluding goodwill) and amortization of goodwill for the Nine months of the consolidated fiscal year are as follows.

(Millions of yen)

|                          | Nine months ended<br>December 31, 2024 | Nine months ended<br>December 31, 2025 |
|--------------------------|--|--|
| Depreciation             | 2,880                                  | 3,142                                  |
| Amortization of goodwill | 33                                     | 33                                     |

(Notes on Segment Information and Other Items)

The Nine months ended December 31, 2024 (from April 1, 2024 to December 31, 2024)

(Millions of yen)

|   | Basic chemicals | Functional chemicals | Healthcare | Trading and Others | Total  | Adjustments *1 | Consolidated *2 |
|---|-----------------|----------------------|------------|--------------------|--------|----------------|-----------------|
| Net sales                               |                 |                      |            |                    |        |                |                 |
| Japan                                   | 25,991          | 6,671                | 2,449      | 10,535             | 45,647 | —              | 45,647          |
| China                                   | —               | 6,503                | 1,283      | 2,549              | 10,336 | —              | 10,336          |
| Asia                                    | 1,469           | 4,134                | 2,165      | 316                | 8,085  | —              | 8,085           |
| Europe                                  | 262             | 3,041                | 3,198      | 133                | 6,635  | —              | 6,635           |
| Others                                  | 391             | 2,767                | 778        | 7                  | 3,945  | —              | 3,945           |
| Revenue from Contracts with Customers   | 28,115          | 23,118               | 9,875      | 13,541             | 74,650 | —              | 74,650          |
| Other Revenue                           | —               | —                    | —          | —                  | —      | —              | —               |
| External sales                          | 28,115          | 23,118               | 9,875      | 13,541             | 74,650 | —              | 74,650          |
| Intersegment sales or reclassifications | 4               | 517                  | —          | 2,608              | 3,130  | (3,130)        | —               |
| Total                                   | 28,119          | 23,635               | 9,875      | 16,150             | 77,781 | (3,130)        | 74,650          |
| Segment income                          | 1,983           | 3,668                | 5,062      | 854                | 11,568 | (929)          | 10,639          |

Notes:

- (1) Adjustments of segment income of ¥ (929) million are corporate expenses not allocated to reportable segments. Most of above-mentioned corporate expenses are not attributable to a reporting segment and related to fundamental research and development.
- (2) Segment income is adjusted to operating income of consolidated statement of income.

The Nine months ended December 31, 2025 (from April 1, 2025 to December 31, 2025)

(Millions of yen)

|   | Basic chemicals | Functional chemicals | Healthcare | Trading and Others | Total  | Adjustments *1 | Consolidated *2 |
|---|-----------------|----------------------|------------|--------------------|--------|----------------|-----------------|
| Net sales                               |                 |                      |            |                    |        |                |                 |
| Japan                                   | 25,719          | 6,107                | 2,474      | 10,401             | 44,702 | —              | 44,702          |
| China                                   | —               | 7,087                | 1,683      | 1,054              | 9,825  | —              | 9,825           |
| Asia                                    | 3,420           | 3,788                | 2,371      | 332                | 9,911  | —              | 9,911           |
| Europe                                  | 632             | 1,916                | 2,959      | 60                 | 5,568  | —              | 5,568           |
| Others                                  | 1,070           | 1,704                | 888        | 16                 | 3,679  | —              | 3,679           |
| Revenue from Contracts with Customers   | 30,842          | 20,604               | 10,376     | 11,865             | 73,688 | —              | 73,688          |
| Other Revenue                           | —               | —                    | —          | —                  | —      | —              | —               |
| External sales                          | 30,842          | 20,604               | 10,376     | 11,865             | 73,688 | —              | 73,688          |
| Intersegment sales or reclassifications | 4               | 522                  | —          | 2,638              | 3,195  | (3,195)        | —               |
| Total                                   | 30,846          | 21,157               | 10,376     | 14,503             | 76,883 | (3,195)        | 73,688          |
| Segment income                          | 4,728           | 3,330                | 5,101      | 770                | 13,931 | (993)          | 12,937          |

Notes:

- (1) Adjustments of segment income of ¥ (993) million are corporate expenses not allocated to reportable segments. Most of above-mentioned corporate expenses are not attributable to a reporting segment and related to fundamental research and development.
- (2) Segment income is adjusted to operating income of consolidated statement of income.